Skip to content

Comparative Evaluation of Trayushnadi Guggulu and Atorvastatin in Dyslipidemia

A CLINICAL STUDY ON THE COMPARATIVE EFFICACY OF TRAYUSHNADI GUGGULU AND ATORVASTATIN IN THE MANAGEMENT OF DYSLIPIDEMIA: A RANDOMIZED CONTROLLED TRIAL - TAD Trail

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/04/107444
Enrollment
60
Registered
2026-04-02
Start date
Unknown
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E785- Hyperlipidemia, unspecified

Interventions

None listed

Sponsors

State Ayurvedic College And Hospital lucknow
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Age between 21 to 60 years. Either male or female patients. Patients diagnosed with dyslipidemia based on any one of the following: Total cholesterol more than 200 mg per dl Triglycerides more than 150 mg per dl LDL cholesterol more than 130 mg per dl HDL cholesterol less than 40 mg per dl Patients willing to participate and able to provide written informed consent. Patients available for regular follow up during the study period.

Exclusion criteria

Exclusion criteria: Age less than 21 years or more than 60 years. Patients with uncontrolled diabetes mellitus or uncontrolled hypertension. Patients with history of cardiovascular diseases such as coronary artery disease, myocardial infarction or ischemic heart disease. Patients with renal or hepatic disorders. Patients with hypothyroidism or other secondary causes of dyslipidemia. Patients with hereditary dyslipidemia or drug induced dyslipidemia. Pregnant or lactating women. Patients with known allergy or hypersensitivity to study drugs. Patients not willing to participate in the study.

Design outcomes

Primary

MeasureTime frame
Change in lipid profile parameters (total cholesterol, triglycerides, LDL and HDL) from baseline to end of treatmentTimepoint: Baseline, Day 15, Day 30, Day 45 and Day 60

Secondary

MeasureTime frame
Assessment of safety by liver function test and kidney function test at baseline and Day 60; assessment of body mass index changes at baseline and Day 60; assessment of clinical symptoms of Medoroga at baseline, Day 30 and Day 60Timepoint: Baseline, Day 30 and Day 60

Countries

India

Contacts

Public ContactDr keshav singh

State Ayurvedic College and Hospital Lucknow

dr.richagarg78@gmail.com9452278875

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026